Glofitamab — Drug Intelligence | 16 EU Trials

Filter these 16 trials by condition, phase, country and more.

Open in Search →

16 Registered trials

8 Recruiting

6 Completed trials

10 Sponsors

14 Countries

Phase III

Phase II

Phase I/II

Phase III: 2 Phase II/III: 1 Phase II: 8 Phase I/II: 4 Phase I (FiH): 1

Oversight events:

2 urgent safety measures 2 unexpected events across 3 trials

View oversight register →

Indications tested

Diffuse large B-cell lymphoma refractory 3 Mantle cell lymphoma recurrent 2 Richter's syndrome 2 Diffuse large B-cell lymphoma recurrent 2 Mantle cell lymphoma refractory 2 B-cell lymphoma 1 Follicular lymphoma stage I 1 Mantle cell lymphoma 1 Marginal zone lymphoma refractory 1 Marginal zone lymphoma recurrent 1 Waldenstrom´s macroglobulinaemia refractory 1 Follicular lymphoma stage III 1

Sponsors using this IMP

F. Hoffmann-La Roche AG 6 Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH 2 BeOne Medicines AG 1 Fondazione Italiana Linfomi Ets 1 French Innovative Leukemia Organization 1 Klinikum der Universitaet Muenchen AöR 1 Lymphoma Academic Research Organisation 1 LYSARC 1 Pfizer Inc. 1 Ryvu Therapeutics S.A. 1

All trials

16 total

Study carried out at multiple centers to test Glofitamab in patients with mantle cell lymphoma who did not respond well to, or relapsed afte… Pending

2025-523428-39-00 Phase II 1 country Fondazione Italiana Linfomi Ets
Double-T - Improving outcomes in high-risk 2nd line relapsed/refractory Large B-Cell Lymphoma patients eligible for CAR-T-cell therapy with … Pending

2025-523806-34-00 Phase II 1 country Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
PIRTOBRUTINIB AND GLOFITAMAB IN MANTLE CELL LYMPHOMA Recruiting

2024-512922-27-00 Phase II 5 countries Klinikum der Universitaet Muenchen AöR
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell… Recruiting

2024-516234-35-00 Phase I/II 3 countries BeOne Medicines AG
A phase II, multicenter, open-label study evaluating Glofitamab in combination with Venetoclax plus Zanubrutinib or Venetoclax alone in subj… Recruiting

2023-506706-40-00 Phase II/III 2 countries Lymphoma Academic Research Organisation
Study of MEN1703 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Recruiting

2024-513098-31-00 Phase II 3 countries Ryvu Therapeutics S.A.
FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab … Recruiting

2022-501554-11-00 Phase II 1 country French Innovative Leukemia Organization
A Study to Compare the Efficacy and Safety of Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory… Recruiting

2023-503206-37-00 Phase III 4 countries F. Hoffmann-La Roche AG
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination with Che… Recruiting

2023-504264-41-00 Phase I/II 8 countries F. Hoffmann-La Roche AG
A Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent … Recruiting

2023-505625-14-00 Phase I (FiH) 8 countries F. Hoffmann-La Roche AG
A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate pol… Ended

2024-513949-37-00 Phase II 2 countries Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
A Study to Evaluate the Efficacy and Safety of Glofitamab in Combination with Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination w… Ended

2023-506899-27-00 Phase III 6 countries F. Hoffmann-La Roche AG
A study to look at how safe and effective glofitamab plus R-CHOP in ctDNA high-risk people with untreated diffuse large B-cell lymphoma Ended

2023-504994-19-00 Phase II 5 countries F. Hoffmann-La Roche AG
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, a CD19 targeted 4-1BB l… Ended

2022-502616-37-00 Phase I/II 5 countries F. Hoffmann-La Roche AG
BiCAR Therapy - A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas after CAR T-cells th… Ended

2023-508301-25-00 Phase II 1 country LYSARC
C4971006: A Study to Learn About the Effects of 2 Study Medicines (Maplirpacept [PF-07901801] and Glofitamab) When Given Together in People … Ended

2022-502822-41-00 Phase I/II 3 countries Pfizer Inc.

Showing 1–16 of 16 trials

← All drugs A–Z